Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gossamer Bio, Inc. - Common Stock (NQ:GOSS)

0.4322 -0.0178 (-3.96%)
Streaming Delayed Price Updated: 12:38 PM EDT, Apr 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gossamer Bio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Gossamer Bio Presented Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress
From Gossamer Bio, Inc.
Via Business Wire
News headline image
Gossamer Bio to Present Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress
From Gossamer Bio, Inc.
Via Business Wire
News headline image
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Gossamer Bio, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Gossamer Bio, Inc.
Via Business Wire
News headline image
Gossamer Bio Announces Third Quarter 2024 Financial Results and Provides Business Update
From Gossamer Bio, Inc.
Via Business Wire
News headline image
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Gossamer Bio, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Gossamer Bio Announces Data Presentations at the European Respiratory Society Congress 2024
From Gossamer Bio, Inc.
Via Business Wire
News headline image
GOSS Stock Earnings: Gossamer Bio Misses EPS, Misses Revenue for Q2 2024 ↗
GOSS stock results show that Gossamer Bio missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Gossamer Bio Announces Second Quarter 2024 Financial Results and Provides Business Update
From Gossamer Bio, Inc.
Via Business Wire
News headline image
Gossamer Bio's Clean Safety Profile Differentiates It From Merck, Analyst Says ↗
Oppenheimer initiated coverage on Gossamer Bio, highlighting seralutinib's clean long-term safety profile for pulmonary arterial hypertension. Seralutinib shows potential in underserved markets. 
Via Benzinga
News headline image
Gossamer Bio And 2 Other Stocks Under $2 Insiders Are Buying ↗
 
Via Benzinga
News headline image
Why Kaival Brands Innovations Shares Are Trading Lower By 47%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
 
Via Benzinga
News headline image
The Penny Stock Pundits: 3 Companies Poised to Become the Talk of Wall Street ↗
Taking a small position in these penny stocks today could have you sitting on a sizable gain by the time Wall Street starts to pile in. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Gossamer Bio, Inc.
Via Business Wire
News headline image
Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference
From Gossamer Bio, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Gossamer Bio, Inc.
Via Business Wire
News headline image
GOSS Stock Earnings: Gossamer Bio Misses EPS for Q1 2024 ↗
GOSS stock results show that Gossamer Bio missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update
From Gossamer Bio, Inc.
Via Business Wire
News headline image
Gossamer Bio Collaborates With Italian Drugmaker Chiesi To Advance Lung Health Solutions Worldwide ↗
Gossamer Bio partners with Chiesi Farmaceutici to develop and market seralutinib globally, targeting pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung... 
Via Benzinga
News headline image
Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications
From Gossamer Bio, Inc.
Via Business Wire
News headline image
Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine
From Gossamer Bio, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors
From Gossamer Bio, Inc.
Via Business Wire
News headline image
Goldman Sachs Maintains Buy Rating for Gossamer Bio: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
GOSS Stock Earnings: Gossamer Bio Meets EPS for Q4 2023 ↗
GOSS stock results show that Gossamer Bio met analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.